Rapaflo (silodosin), a new uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology. Rapaflo was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals.

In an analysis of data pooled from two phase-3 studies, patients taking Rapaflo demonstrated statistically significant symptom relief versus placebo within three to four days of starting treatment, and remained significant throughout the 12-week study period.

"The severity of urinary symptoms appears to depend in part on smooth muscle tone in the prostate and bladder neck, which is mediated by alpha 1A adrenoreceptors," said Leonard S Marks, author of the study and professor of urology at the Geffen School of Medicine, the University of California at Los Angeles. "The data indicate that Rapaflo (silodosin) induces effective relaxation of the targeted prostatic muscle tissue, with a low incidence of vasodilatory and orthostatic effects. Rapaflo (silodosin) is a fast acting, effective and safe treatment for the signs and symptoms associated with BPH."

BPH is the number one reason patients visit urologists and is characterized by urination problems, including decreased urine flow, more frequent urination and nocturia.

Rapaflo is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. Rapaflo maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate.